Ntla stock forecast.

Intellia Therapeutics Inc’s ( NTLA) price is currently down 4.05% so far this month. During the month of April, Intellia Therapeutics Inc’s stock price has reached a high of $40.67 and a low of $34.41. Over the last year, Intellia Therapeutics Inc has hit prices as high as $76.45 and as low as $32.44. Year to date, Intellia Therapeutics Inc ...

Ntla stock forecast. Things To Know About Ntla stock forecast.

Teradyne Stock Forecast 05-20-2022. Forecast target price for 05-20-2022: $ 106.94. Positive dynamics for Teradyne shares will prevail with possible volatility of 2.637%. Pessimistic target level: 105.08. Optimistic target level: 107.92.Dec 1, 2023 · 2014. 598. John Leonard. https://www.intelliatx.com. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary ... Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. Shares of Intellia Therapeutics, Inc. (NTLA) have gained 23.5% over the past four weeks to close the last trading session at $43.19, but there could still be a solid upside left in the stock if ...

What this means: InvestorsObserver gives Intellia Therapeutics Inc. (NTLA) an overall rank of 36, which is below average. Intellia Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 36 means that 64% of stocks appear more favorable to our system.The average twelve-month price prediction for Intellia Therapeutics is $77.70 with a high price target of $136.00 and a low price target of $40.00. Learn more on NTLA's analyst rating history. Do Wall Street analysts like Intellia Therapeutics more than its competitors?Even after rising 30% so far this year, shares of Intellia Therapeutics ( NTLA 4.88%) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive ...

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, …February 6, 2023 at 9:35 AM · 6 min read. The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear ...

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Gas prices are at a record high, and experts are forecasting that prices could go higher this summer — perhaps $5 or even over $6 a gallon. By clicking "TRY IT", I agree to receive newsletters and promotions from Money and its partners. I a...We've seen plenty of personal finance tools designed to help you track what you're spending, but web site PocketSmith is an impressive new web-based personal finance tool with an emphasis on forecasting your financial future. We've seen ple...Intellia was founded in 2014 and went public in 2016, raising net proceeds of $112.1 million at $18 per share. The stock currently trades around $36.00 a share, translating to a market cap of $3. ...Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance

A high-level overview of Intellia Therapeutics, Inc. (NTLA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Intellia Therapeutics is a genome editing company that develops curative therapeutics for various diseases. The company's stock price, news, and analysis are shown on the web page, as well as its market cap, P/E ratio, dividend yield, and price target. The company has a consensus rating of Moderate Buy and a forecasted upside of 228.3%.

Three Fool.com contributors have identified beaten-down stocks of relatively small companies that could soar this year. Here's why they picked CRISPR Therapeutics ( CRSP 4.39%), Exelixis ( EXEL 0. ...The anecdotal wisdom is that the way to outperform the market this year has been to flock to the Magnificent Seven stocks (AAPL, AMZN, Google, META, MSFT, Latest NewsStock Price Forecast The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00.Intellia Therapeutics Stock Chart and Share Price Forecast, Short-Term "NTLA" Stock Prediction for Next Days and Weeks Walletinvestor.com Intellia Therapeutics Inc (NTLA) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024Mar 3, 2022 · Intellia Therapeutics. Market Cap. $3B. Today's Change. (-1.23%) -$0.38. Current Price. $30.65. Price as of November 27, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ... Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance

Intellia Therapeutics last released its quarterly earnings results on November 9th, 2023. The reported ($1.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.52) by $0.14. The firm earned $11.99 million during the quarter, compared to the consensus estimate of $12.45 million.What this means: InvestorsObserver gives Intellia Therapeutics Inc. (NTLA) an overall rank of 36, which is below average. Intellia Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 36 means that 64% of stocks appear more favorable to our system.People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.The average Editas Medicine stock forecast 2024 represents a 3.79% increase from the last price of $10.5299997329712. For Editas Medicine stock forecast for 2025, 12 predictions are offered for each month of 2025 with average Editas Medicine stock forecast of $10.98, a high forecast of $12.02, and a low forecast of $10.15.Goldman Sachs initiated Intellia Therapeutics ( NTLA +4.5%) with a Buy rating, PT $33; stock has surged 94% in the past 6 months, Wall Street Analysts (PT, $30) and Quant Rating is Bullish ...The 12-month stock price forecast is $69.88, which is an increase of 1.79% from the latest price. Price Target. $69.88 (1.79% upside) Analyst Consensus: Buy. Stock Forecasts. News. All; Videos; Press Press Releases; Conversation; ... Intellia Therapeutics Inc. NTLA, -0.28% shares gained 6.4% premarket on Monday after the clinical stage …View the latest Intellia Therapeutics Inc. (NTLA) stock price, news, historical charts, analyst ratings and financial information from WSJ.

View the latest Intellia Therapeutics Inc. (NTLA) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The race to develop a new gene therapy with CRISPR took some interesting turns recently. On the same day that Intellia Therapeutics (NTLA-1.23%) dazzled the medical community with clinical trial ...Intellia Therapeutics Inc (NTLA) Stock Price & News - Google Finance Home NTLA • NASDAQ Intellia Therapeutics Inc Follow Share $30.93 After Hours: $31.14 (0.68%) +0.21 Closed: Nov 29, 5:10:43... 2014. 598. John Leonard. https://www.intelliatx.com. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary ...It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...The stock is trading at $62.69 and its $108.64 indicates a 73% one-year gain lying ahead for NTLA. (See NTLA stock forecast on TipRanks)To find good ideas for stocks trading at attractive ...In the same period, the company plans to submit an IND for NTLA-3001, its therapy for alpha-1 antitrypsin deficiency-related lung disease that's presently in early-stage trials.

Intellia Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ... Stock Price Target NTLA. High $ 145.00: Median $ 72.00: Low $ 29.00: Average $ 76.00: Current ...

View Intellia Therapeutics, Inc NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and...

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Track Intellia Therapeutics Inc (NTLA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNov 30, 2023 · Stock Price Forecast. According to 20 stock analysts, the average 12-month stock price forecast for NTLA stock stock is $77.4, which predicts an increase of 149.44%. The lowest target is $39 and the highest is $136. On average, analysts rate NTLA stock stock as a buy. Complete Intellia Therapeutics Inc. stock information by Barron's. View real-time NTLA stock price and news, along with industry-best analysis.Nov 29, 2023 · See the latest Intellia Therapeutics Inc stock price (NTLA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The Intellia Therapeutics Inc stock price gained 2.54% on the last trading day (Friday, 24th Nov 2023), rising from $30.26 to $31.03. During the last trading day the stock fluctuated 5.87% from a day low at $30.13 to a day high of $31.90. The price has risen in 6 of the last 10 days and is up by 24.32% over the past 2 weeks.For their last quarter, Intellia Therapeutics (NTLA) reported earnings of -$1.40 per share, missing the Zacks Consensus Estimate of -$1.32 per share. This reflects a negative earnings surprise of ...Intellia Therapeutics Inc’s ( NTLA) price is currently down 4.05% so far this month. During the month of April, Intellia Therapeutics Inc’s stock price has reached a high of $40.67 and a low of $34.41. Over the last year, Intellia Therapeutics Inc has hit prices as high as $76.45 and as low as $32.44. Year to date, Intellia Therapeutics Inc ...The average Intellia Therapeutics stock price prediction forecasts a potential upside of 203.75% from the current NTLA share price of $25.50. What is NTLA's forecast return on assets (ROA) for 2023-2026?Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to ...The average Marvell Technology stock price prediction forecasts a potential upside of 25.7% from the current MRVL share price of $56.03. What is MRVL's forecast return on equity (ROE) for 2024-2026? (NASDAQ: MRVL) forecast ROE is …Nov 30, 2023 · Stock Price Forecast. According to 20 stock analysts, the average 12-month stock price forecast for NTLA stock stock is $77.4, which predicts an increase of 149.44%. The lowest target is $39 and the highest is $136. On average, analysts rate NTLA stock stock as a buy.

(See NTLA stock forecast)Pacific Biosciences (PACB)We’ll stay in the biotech space for the next Wood-backed name, although Pacific Biosciences operates in a different segment.Analysts are bullish on NTLA stock. It currently has a mean price target of $97.19 which would be a gain of over 154% from the current price and institutional investors own approximately 85% of ...The race to develop a new gene therapy with CRISPR took some interesting turns recently. On the same day that Intellia Therapeutics (NTLA-1.23%) dazzled the medical community with clinical trial ...Instagram:https://instagram. geely automobiledoes root insurance offer sr22pimco total return fundwholefoods stocks Find real-time NTLA - Intellia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. charles schwab bank sweeplouis navillier The Invitae Corp ( NVTA) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $3.8754, representing a +617.26% increase from the current price of $0.5403. The highest analyst price target is $7.6988, and the lowest is $0.0519. Based on our technical indicators, the current sentiment is ...That’s a key advantage of investing in large-cap stocks. These drugs delivered over $9 billion in revenue for the company. That revenue goes along with positive earnings per share of $12.83 in ... portfolio tracking Intellia Therapeutics (NTLA) Stock Forecast & Price Prediction. Estimation of the future price movement of Intellia Therapeutics stock, based on various factors such as …View the latest Intellia Therapeutics Inc. (NTLA) stock price, news, historical charts, analyst ratings and financial information from WSJ.